Adults 70 to 95, any sex, with Mobility Limitation or Aging. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Walking Speed Change From BaselinePrimary· Measured at follow up visit (approximately three weeks after baseline)
Change in the fastest safe walking speed during a two minute walk test
Group
Value
95% CI
Active tDCS
0.052
± 0.098
Sham tDCS
-0.026
± 0.052
Timed up and go Completion Time From BaselineSecondary· Measured at follow up visit (approximately three weeks after baseline)
Change in the time to complete a 7 meter timed up and go
Group
Value
95% CI
Active tDCS
-0.22
± 1.70
Sham tDCS
0.31
± 1.73
Sponsor's own description
Older adults often have difficulty performing complex walking tasks leading to increased fall incidence and subsequent injury. Even in the best clinical settings, it may not be possible for patients or clinicians to dedicate the time and financial resources needed to enact lasting improvements. The study will investigate the use of non-invasive brain stimulation and motor imagery practice within participants homes to assess study design feasibility and potential for mobility improvement.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07125378 — Living Independence Through Functional Training
· Phase 1, PHASE2
· recruiting
NCT07174973 — Innovative Approaches to Enhance Balance and Neuroplasticity in Multiple Sclerosis
· NA
· recruiting
NCT07308353 — Comparative Effects Of Exergaming And Otago Exercise On Anticipatory Postural Control And Sensory Integration In Older A
· NA
· active not recruiting
NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease
· Phase 3
· recruiting
NCT06592144 — TESTO-TRIAL: Use of Testosterone in Critically Ill Patients
· Phase 4
· active not recruiting
Other University of Florida trials
Trials by the same sponsor.
NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
· NA
· not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia
· NA
· suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl
· Phase 2, PHASE3
· not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
· Phase 1
· not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 22 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583578.